India Exits Vaccine-Making Business By Transforming Four Units
This article was originally published in PharmAsia News
India is no longer in the vaccine business, the country's health minister said. Until now, the government had operated four units to produce vaccines in case of emergencies, but health ministry officials say that backup no longer is necessary. Instead, the facilities are to be used for diagnostic testing, beginning in a few months, with unit employees retrained for their new jobs. The manufacturing licenses of the four units had been suspended in January because they no longer met good manufacturing practices standards. (Click here for more
You may also be interested in...
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.